drugset / Trial / NCT07630545
A Phase I Study in Healthy Volunteers and Parkinson's Disease (PD) Patients.
Phase 1
Recruiting
106 enrolled
Mission Therapeutics
Michael J. Fox Foundation for Parkinson's Research · collabParkinson's UK · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this trial is to learn if MTX325 can be developed as a potential disease-modifying treatment for Parkinson's Disease. Parts 1-4 complete, Part 5 (multiple doses in patients with Parkinson's Disease) in progress.
Timeline
- Start
- 2023-11-30
- Primary completion
- 2027-06-30
- Completion
- 2027-12-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | MTX325 | Unknown | 1.5 mg | Oral |
| Comparator | MTX325 | Unknown | 20 mg | Oral |
| Comparator | MTX325 | Unknown | 100 mg | Oral |